Close
What would you like to look for?
Site search
Search filters

Warteck Invest completes Capital Increase

18 June 2019
4 June 2019

VISCHER advises on the capital increase of Warteck Invest AG as transaction counsel. Warteck Invest is one of the oldest real estate companies listed on the SIX Swiss Exchange and is focusing on residential and business properties...

Oculis in-licenses novel phase II-stage Anti-TNF alpha antibody fragment

9 January 2019
19 February 2019

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. The...

Kuros Biosciences AG completes rights offering and share placement

17 December 2018
19 February 2019

Kuros Biosciences (SIX: KURN) completes a rights offering and share placement in which a total of 8,013,306 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00...

Polyphor closes IPO on SIX Swiss Exchange

18 May 2018

Polyphor, clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibiotics and other specialty pharma products for severe or life-threatening diseases, set the offer price for its shares...

Polyphor launches IPO on SIX Swiss Exchange and sets price range

27 April 2018

Polyphor Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of inno-vative antibiotics and other specialty pharma products for severe or life-threatening diseases, today announces the launch...

Medartis completes IPO and listing on the SIX Swiss Exchange

28 March 2018

Medartis Holding AG, a leading original equipment manufacturer (OEM) specialized in medical devices for internal surgical bone fixation, completed its initial public offering (IPO) on the SIX Swiss Exchange on 23 March 2018. Based...

Medartis announces plans to IPO and list on the SIX Swiss Exchange

8 March 2018

Medartis Holding AG, a leading original equipment manufacturer (OEM) specialized in medical devices for internal surgical bone fixation, announces its intention to conduct an initial public offering (IPO) on the SIX Swiss Exchange...

Oculis CHF 20m Financing Round

11 January 2018

Oculis, a clinical-stage biotechnology company focused on the development of non-invasive topical treatment for back-of-the-eye diseases, announced the completion of a CHF 20m Series B financing. The round involved a syndicate of...

VISCHER advises Syngenta on divestment of sugar beet seeds business

19 October 2017

VISCHER advises Syngenta on all aspects of Swiss law in its divestment of the global sugar beet seeds business. Syngenta is one of the largest agrichemical groups worldwide, with a workforce of more than 28,000 across 90...

Boston Scientific closes acquisition of Symetis

22 May 2017

Symetis has been acquired by Boston Scientific (NYSE:BSX) for $435 million in an all cash, up-front payment. Symetis is a medical technology company specializing in the development, manufacturing and marketing of percutaneous...